In patients with confirmed ovarian cancer, VEGF, malondialdehyde, and ceruloplasmin had prognostic value, both in terms of progression-free survival and overall survival, especially in patients with the residual macroscopic disease. This evidence concerns the gene CP and ovarian carcinoma.